Recruiting

Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension

This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, anterior segment optical coherence tomography (AS-OCT), and OCT gonioscopy will be performed at baseline and after approximately 14 days of treatment. The primary objective is to assess changes in trabecular meshwork…

ClinicalTrials.gov IDNCT07588152

PhasePHASE4

Enrollment50

SponsorIndiana University

Age18 Years and older

SexALL

I'm interested View official listing

Conditions studied

Glaucoma, Ocular Hypertension

About this study

Interventions

Drug: Netarsudil Ophthalmic Solution (Rhopressa) — Netarsudil ophthalmic solution is an FDA-approved Rho kinase inhibitor indicated for the treatment of ocular hypertension and open-angle glaucoma. In this study, it will be administered once daily in the evening for approximately 14 days.
Other: Artificial Tears (AT) — Artificial tears will be used as a placebo control and administered once daily in the evening for approximately 14 days. These drops are not expected to lower intraocular pressure or alter trabecular meshwork structure.

Primary outcomes

Change in Trabecular Meshwork Lamellae Spacing (Baseline to 14-21 days after initiation of treatment)

Eligibility information

Inclusion Criteria: * Adults aged 18 years or older * Diagnosis of ocular hypertension or open-angle glaucoma * Eye examination within the past year * For glaucoma subjects: structural (optic nerve and/or retinal nerve fiber layer) and functional (visual field) findings consistent with glaucoma * Best-corrected visual acuity of 20/100 or better * Open anterior chamber angle as confirmed by gonioscopy and anterior segment optical coherence tomography (AS-OCT) * Intraocular pressure between 18 and 34 mmHg (treatment-naïve or after washout, if applicable) Exclusion Criteria: * Known intolerance to netarsudil ophthalmic solution * Corneal scarring or active corneal disease that would interfere with imaging * Inability to tolerate gonioscopy procedures * Females of childbearing potential who are not using effective contraception or are not sterile * Any condition that, in the opinion of the investigator, would place the subject at increased risk or interfere with study completion

Study locations

Indiana Universtiy School of Optometry, Bloomington, Indiana 47405 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-14.